---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-005593"
form_type: "8-K"
ticker: "ZVRA"
cik: "0001434647"
company_name: "ZEVRA THERAPEUTICS, INC."
filed_at: "2023-03-07T23:59:59+00:00"
generated_at: "2026-06-18T09:35:31.803709+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Zevra reports Q4 net loss $9.0M ($0.26/sh); cash $102.9M; arimoclomol NDA resubmission on track for Q3 2023

## Summary
- Q4 net revenue $2.3M (vs $2.6M in Q4 2021); net loss ($9.0M) or ($0.26)/share vs ($2.7M)/($0.08).
- FY 2022 net revenue $10.5M (down from $28.7M); net loss ($41.5M) or ($1.20)/share vs ($62.9M)/($2.11) in 2021.
- Cash, cash equivalents and investments $102.9M as of Dec 31, 2022; cash runway extended into 2026.
- Arimoclomol NDA resubmission for NPC anticipated as early as Q3 2023.
- KP1077 Phase 2 trial for IH: interim data expected as early as Q3 2023, top-line by year-end 2023.

## SEC filing metadata
- accession: 0001437749-23-005593
- form_type: 8-K
- ticker: ZVRA
- cik: 0001434647
- company_name: ZEVRA THERAPEUTICS, INC.
- filed_at: 2023-03-07T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434647/000143774923005593/0001437749-23-005593-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434647/000143774923005593/kmph20221130_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-005593
- JSON: https://secwatch.observer/filing/0001437749-23-005593.json
- Plain text: https://secwatch.observer/filing/0001437749-23-005593.txt

## Key facts
- Earnings Releases
  ZEVRA THERAPEUTICS, INC. reported fourth quarter and fiscal year ended December 31, 2022 results: revenue $2.3 million, net income ($9.0) million, or ($0.26) per basic and diluted share, EPS ($0.26) per basic and diluted share.
  - Period: fourth quarter and fiscal year ended December 31, 2022
  - Revenue: $2.3 million
  - Net income: ($9.0) million, or ($0.26) per basic and diluted share
  - EPS: ($0.26) per basic and diluted share
  - Result: reported results
  source text: Page 3 Overview of Fourth Quarter (Q4) and Full-Year (FY) 2022 Financial Results: Net revenue for Q4 2022 was $2.3 million, as compared to Q4 2021 net revenue of $2.6 million. Q4 2022 net revenue was primarily driven by ongoing reimbursements received from the French early access program for arimoclomol, AZSTARYS® royalty revenues and consulting fees.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434647/000143774923005593/0001437749-23-005593-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.